March 27 (Reuters) - Rigel Pharmaceuticals Inc RIGL.O:
RIGEL ANNOUNCES SETTLEMENT AGREEMENT RESOLVING TAVALISSE® (FOSTAMATINIB DISODIUM HEXAHYDRATE) PATENT LITIGATION
RIGEL PHARMACEUTICALS INC - UNDER SETTLEMENT, ANNORA TO SELL GENERIC TAVALISSE IN Q2 2032 OR EARLIER
RIGEL PHARMACEUTICALS INC - CO AND ANNORA TERMINATE ALL ONGOING LITIGATION REGARDING TAVALISSE PATENTS
Source text: ID:nPn7Fq2Y5a
Further company coverage: RIGL.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.